Cleminorexton
| Clinical data | |
|---|---|
| Other names | ORX750; ORX-750 |
| Routes of administration | Oral[1] |
| Drug class | Orexin receptor agonist; Orexin OX2 receptor agonist; Wakefulness-promoting agent |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H24F4N2O4S |
| Molar mass | 512.52 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cleminorexton (INN; former developmental code name ORX750) is an orexin OX2 receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia.[2][3][4][5][1] It is taken orally.[1] The drug was originated by Orexia, was subsequently developed by Centessa Pharmaceuticals, and is now being developed by Eli Lilly and Company.[2][3][5] As of November 2025, it is in phase 2 clinical trials for narcolepsy and idiopathic hypersomnia.[2][3]
See also
References
- ^ a b c Manalac T (31 March 2026). "Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda". BioSpace. Retrieved 6 April 2026.
- ^ a b c "ORX 750". AdisInsight. Springer Nature Switzerland AG. 11 November 2025. Retrieved 6 April 2026.
- ^ a b c "Delving into the Latest Updates on Cleminorexton with Synapse". Synapse. PatSnap. 3 April 2026. Retrieved 6 April 2026.
- ^ Shahzadi M, Monderer R, Thorpy MJ (November 2025). "Understanding idiopathic hypersomnia: diagnosis, pathophysiology, and management". Current Opinion in Pulmonary Medicine. 31 (6): 597–604. doi:10.1097/MCP.0000000000001221. PMID 40990641.
- ^ a b Waldron J (31 March 2026). "Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play". Fierce Biotech. Retrieved 6 April 2026.